ATE445639T1 - Globularer aufbau vom amyloid-beta- protein und deren verwendungen - Google Patents

Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Info

Publication number
ATE445639T1
ATE445639T1 AT04027742T AT04027742T ATE445639T1 AT E445639 T1 ATE445639 T1 AT E445639T1 AT 04027742 T AT04027742 T AT 04027742T AT 04027742 T AT04027742 T AT 04027742T AT E445639 T1 ATE445639 T1 AT E445639T1
Authority
AT
Austria
Prior art keywords
addls
activity
formation
amyloid beta
compounds
Prior art date
Application number
AT04027742T
Other languages
English (en)
Inventor
Grant A Kraft
William L Klein
Brett A Chromy
Mary P Lambert
Caleb E Finch
Todd Morgan
Pat Wals
Irina Rozovsky
Ann Barlow
Original Assignee
Univ Southern California
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23454671&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE445639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California, Univ Northwestern filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE445639T1 publication Critical patent/ATE445639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
AT04027742T 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen ATE445639T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36923699A 1999-08-04 1999-08-04

Publications (1)

Publication Number Publication Date
ATE445639T1 true ATE445639T1 (de) 2009-10-15

Family

ID=23454671

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04027742T ATE445639T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen
AT00952571T ATE283285T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT00952571T ATE283285T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Country Status (9)

Country Link
EP (2) EP1200470B1 (de)
JP (1) JP4796725B2 (de)
AT (2) ATE445639T1 (de)
AU (1) AU6524500A (de)
CA (1) CA2381323C (de)
DE (2) DE60043165D1 (de)
ES (1) ES2235926T3 (de)
HK (1) HK1047944A1 (de)
WO (1) WO2001010900A2 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
PL218883B1 (pl) 2000-02-24 2015-02-27 Lilly Co Eli Kompozycja farmaceutyczna zawierająca przeciwciało do zastosowania w leczeniu klinicznej lub przedklinicznej choroby Alzheimera
WO2002003911A2 (en) 2000-07-07 2002-01-17 Lars Lannfelt Prevention and treatment of alzheimer's disease
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
PT1944040E (pt) 2001-08-17 2012-10-31 Univ Washington Método de avaliação para a doença de alzheimer
EP1288226A1 (de) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modifizierung der Geneexpression der Mitglieder von "Toll"-ähnlicher Rezeptorfamilie zur Beeinflussung der Neurodegeneration und der Neuroprotektion im menschlichen Zentralnervensystem
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1535056A1 (de) * 2002-07-31 2005-06-01 Solvias AG Vorrichtung und messverfahren
WO2004031400A2 (en) * 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
JP2008500286A (ja) * 2004-05-14 2008-01-10 ノースウエスタン ユニバーシティ Ａｄｄｌ受容体を含む組成物、関連する組成物、および関連する方法
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
DE602006012459D1 (de) 2005-03-05 2010-04-08 Abbott Gmbh & Co Kg Screening-verfahren, verfahren zur aufreinigung nichtdiffundierbarer a-beta-oligomere, selektive antikörper gegen diese nichtdiffundierbaren a-beta-oligomere und verfahren zur herstellung dieser antikörper
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
TW200726774A (en) * 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
SG2014013437A (en) 2005-11-30 2014-07-30 Abbott Lab Monoclonal antibodies and uses thereof
EP1963363A2 (de) 2005-11-30 2008-09-03 Abbott Laboratories Verfahren zur herstellung rekombinanter formen von humanem beta-amyloid-protein und verwendung dieser proteine
NZ567888A (en) 2006-03-23 2010-08-27 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008088983A1 (en) 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
DK2448968T3 (da) * 2009-06-29 2021-04-12 Bioarctic Ab ANTISTOFFER SOM ER SELEKTIVE FOR N-TERMINAL-TRUNKEREDE AMYLOID-ß PROTOFIBRILLER/OLIGOMERER
EP2368558A1 (de) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azoverbindungen zur Reduzierung der Bildung und der Toxizität von Amyloid-Beta-Aggregationszwischenprodukten
MX360403B (es) 2010-04-15 2018-10-31 Abbvie Inc Proteinas de union a amiloide beta.
JP6147665B2 (ja) 2010-08-14 2017-06-14 アッヴィ・インコーポレイテッド アミロイドベータ結合タンパク質
WO2013009667A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. Method for detection of amyloid beta oligomers in a fluid sample and uses thereof
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
KR102564384B1 (ko) 2014-07-10 2023-08-07 바이오악틱 에이비 개선된 Aβ 프로토피브릴 결합 항체
US20190015361A1 (en) * 2017-07-17 2019-01-17 Maxwell Biosciences, Inc. Polytherapy modulating cathelicidin gene exprtession modulation for the treatment of alzheimer's disease and other conditions
WO2023107830A1 (en) * 2021-12-06 2023-06-15 The Board Of Trustees Of The Leland Stanford Junior University Amyloid oligomer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
JP2001514661A (ja) * 1997-03-11 2001-09-11 ザ ジェネラル ホスピタル コーポレイション アルツハイマー病の処置における使用のための薬剤の同定

Also Published As

Publication number Publication date
ATE283285T1 (de) 2004-12-15
EP1571158B1 (de) 2009-10-14
CA2381323A1 (en) 2001-02-15
HK1047944A1 (zh) 2003-03-14
EP1571158A2 (de) 2005-09-07
AU6524500A (en) 2001-03-05
DE60016227T2 (de) 2005-12-15
EP1571158A3 (de) 2007-03-14
EP1200470B1 (de) 2004-11-24
CA2381323C (en) 2009-10-06
JP2003510023A (ja) 2003-03-18
EP1200470A2 (de) 2002-05-02
WO2001010900A3 (en) 2001-08-30
ES2235926T3 (es) 2005-07-16
DE60016227D1 (de) 2004-12-30
WO2001010900A2 (en) 2001-02-15
DE60043165D1 (de) 2009-11-26
JP4796725B2 (ja) 2011-10-19

Similar Documents

Publication Publication Date Title
ATE445639T1 (de) Globularer aufbau vom amyloid-beta- protein und deren verwendungen
ATE349467T1 (de) Amyloid beta protein (globularer aufbau und seine verwendung)
WO2004031400A3 (en) Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
WO2003104437A3 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
DE69841653D1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
ATE362925T1 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2- familie exprimieren
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
WO2007045927A3 (en) Therapeutic agent
NO931889L (no) Protease og beslektede DNA-forbindelser
KR890700666A (ko) 혈관 항응고 단백질, 이를 암호화하는 dna, 이의 제조방법 및 용도
DE60326623D1 (de) P53-bindendes polypeptid
WO2000012703A3 (en) Protein transport-associated molecules
ATE221663T1 (de) Prionbindende proteine und deren verwendungen
ATE385517T1 (de) Interferon ähnliche moleküle, und deren verwendungen
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
ATE277924T1 (de) Aryl-8-azabicyclo(3.2.1)octanes für die behandlung von depression
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2004013629A3 (en) Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs
WO2000078952A8 (en) Human rna metabolism proteins (rmep)
ATE338714T1 (de) Überladebrücke

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties